Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria : 2-year results from two pivotal phase 3 studies
© 2022 Alexion, AstraZeneca Rare Disease. European Journal of Haematology published by John Wiley & Sons Ltd..
OBJECTIVES: The complement component 5 (C5) inhibitor ravulizumab demonstrated non-inferiority to eculizumab following 26 weeks of treatment in complement inhibitor-naïve and complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively). This study aims to describe the results of both studies from 27 weeks to 2 years.
METHODS: Patients (N = 441) continued to receive ravulizumab throughout the extension period. Efficacy endpoints included lactate dehydrogenase (LDH) normalization, transfusion avoidance and fatigue score (FACIT-F). Safety analyses were also performed.
RESULTS: From 27 weeks to 2 years, improvements in LDH levels were maintained in both study populations. Transfusion avoidance was maintained in 81.9% (study 301) and 85.6% (study 302) of patients, and FACIT-F scores remained stable. Ravulizumab was well tolerated, and the incidence of adverse events (AEs) were similar between patients of both studies. Incidence of serious AEs deemed related to ravulizumab treatment was low (<3%).
CONCLUSIONS: This study reports, to date, the longest period of follow-up in over 400 patients with PNH treated with ravulizumab (662 patient-years). Long-term, ravulizumab demonstrated durable efficacy and was well tolerated, highlighting the importance of C5 inhibitors as the mainstay of PNH treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
European journal of haematology - 109(2022), 3 vom: 01. Sept., Seite 205-214 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kulasekararaj, Austin G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.08.2022 Date Revised 15.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.13783 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340313412 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340313412 | ||
| 003 | DE-627 | ||
| 005 | 20231226004851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.13783 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340313412 | ||
| 035 | |a (NLM)35502600 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kulasekararaj, Austin G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria |b 2-year results from two pivotal phase 3 studies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2022 | ||
| 500 | |a Date Revised 15.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Alexion, AstraZeneca Rare Disease. European Journal of Haematology published by John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVES: The complement component 5 (C5) inhibitor ravulizumab demonstrated non-inferiority to eculizumab following 26 weeks of treatment in complement inhibitor-naïve and complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH; studies 301 and 302, respectively). This study aims to describe the results of both studies from 27 weeks to 2 years | ||
| 520 | |a METHODS: Patients (N = 441) continued to receive ravulizumab throughout the extension period. Efficacy endpoints included lactate dehydrogenase (LDH) normalization, transfusion avoidance and fatigue score (FACIT-F). Safety analyses were also performed | ||
| 520 | |a RESULTS: From 27 weeks to 2 years, improvements in LDH levels were maintained in both study populations. Transfusion avoidance was maintained in 81.9% (study 301) and 85.6% (study 302) of patients, and FACIT-F scores remained stable. Ravulizumab was well tolerated, and the incidence of adverse events (AEs) were similar between patients of both studies. Incidence of serious AEs deemed related to ravulizumab treatment was low (<3%) | ||
| 520 | |a CONCLUSIONS: This study reports, to date, the longest period of follow-up in over 400 patients with PNH treated with ravulizumab (662 patient-years). Long-term, ravulizumab demonstrated durable efficacy and was well tolerated, highlighting the importance of C5 inhibitors as the mainstay of PNH treatment | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breakthrough hemolysis | |
| 650 | 4 | |a complement inhibitor | |
| 650 | 4 | |a lactate dehydrogenase | |
| 650 | 4 | |a paroxysmal nocturnal hemoglobinuria | |
| 650 | 4 | |a ravulizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Complement C5 |2 NLM | |
| 650 | 7 | |a Complement Inactivating Agents |2 NLM | |
| 650 | 7 | |a ravulizumab |2 NLM | |
| 650 | 7 | |a C3VX249T6L |2 NLM | |
| 700 | 1 | |a Griffin, Morag |e verfasserin |4 aut | |
| 700 | 1 | |a Langemeijer, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Usuki, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kulagin, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Masayo |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Mujeebuddin, Arshad |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Jun-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jong Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Peffault de Latour, Régis |e verfasserin |4 aut | |
| 700 | 0 | |a 301/302 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Latypova, Aigul |e investigator |4 oth | |
| 700 | 1 | |a Barcellini, Wilma |e investigator |4 oth | |
| 700 | 1 | |a Barraco, Fiorenza |e investigator |4 oth | |
| 700 | 1 | |a Beam, Donald |e investigator |4 oth | |
| 700 | 1 | |a Bettelheim, Peter |e investigator |4 oth | |
| 700 | 1 | |a Borisenkova, Elena |e investigator |4 oth | |
| 700 | 1 | |a Brodsky, Andres |e investigator |4 oth | |
| 700 | 1 | |a Carnley, Benedict |e investigator |4 oth | |
| 700 | 1 | |a Cermak, Jaroslav |e investigator |4 oth | |
| 700 | 1 | |a Chen, Tsai-Yun |e investigator |4 oth | |
| 700 | 1 | |a Chew, Lee Ping |e investigator |4 oth | |
| 700 | 1 | |a Chew, Teng Keat |e investigator |4 oth | |
| 700 | 1 | |a Choi, Chul Won |e investigator |4 oth | |
| 700 | 1 | |a Choi, Yunsuk |e investigator |4 oth | |
| 700 | 1 | |a Chung, Joo Seop |e investigator |4 oth | |
| 700 | 1 | |a De Guibert, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Devos, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Dunaev, Yuri |e investigator |4 oth | |
| 700 | 1 | |a Dwilewicz-Trojaczek, Jadwiga |e investigator |4 oth | |
| 700 | 1 | |a Edahiro, Yoko |e investigator |4 oth | |
| 700 | 1 | |a Elykomov, Iliya |e investigator |4 oth | |
| 700 | 1 | |a Engelberger, Maria Ines |e investigator |4 oth | |
| 700 | 1 | |a Pomponi, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Fuereder, Wolfgang |e investigator |4 oth | |
| 700 | 1 | |a Fujii, Nobuharu |e investigator |4 oth | |
| 700 | 1 | |a Fujiwara, Shinichiro |e investigator |4 oth | |
| 700 | 1 | |a Galieni, Piero |e investigator |4 oth | |
| 700 | 1 | |a Gaya Valls, Anna |e investigator |4 oth | |
| 700 | 1 | |a Girault, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Gomez Almaguer, David |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez Fernandez, F Ataulfo |e investigator |4 oth | |
| 700 | 1 | |a Gritsaev, Sergey |e investigator |4 oth | |
| 700 | 1 | |a Gunduz, Eren |e investigator |4 oth | |
| 700 | 1 | |a Hantaweepant, Chattree |e investigator |4 oth | |
| 700 | 1 | |a Harada, Hiroshi |e investigator |4 oth | |
| 700 | 1 | |a Höglund, Martin |e investigator |4 oth | |
| 700 | 1 | |a Huang, Wei-Han |e investigator |4 oth | |
| 700 | 1 | |a Husin, Azlan |e investigator |4 oth | |
| 700 | 1 | |a Ikezoe, Takayuki |e investigator |4 oth | |
| 700 | 1 | |a Ishiyama, Ken |e investigator |4 oth | |
| 700 | 1 | |a Ito, Yoshikazu |e investigator |4 oth | |
| 700 | 1 | |a Jang, Jun Ho |e investigator |4 oth | |
| 700 | 1 | |a Jo, Deog-Yeon |e investigator |4 oth | |
| 700 | 1 | |a Kang, Ka-Won |e investigator |4 oth | |
| 700 | 1 | |a Kennedy, James |e investigator |4 oth | |
| 700 | 1 | |a Kim, Hyo Jung |e investigator |4 oth | |
| 700 | 1 | |a Kim, Jeong-A |e investigator |4 oth | |
| 700 | 1 | |a Kim, Jin Seok |e investigator |4 oth | |
| 700 | 1 | |a Kimura, Fumihiko |e investigator |4 oth | |
| 700 | 1 | |a Kobune, Masayoshi |e investigator |4 oth | |
| 700 | 1 | |a Kosugi, Hiroshi |e investigator |4 oth | |
| 700 | 1 | |a Kulagin, Alexander |e investigator |4 oth | |
| 700 | 1 | |a Kulasekararaj, Austin |e investigator |4 oth | |
| 700 | 1 | |a Lai, Kuan-Ming |e investigator |4 oth | |
| 700 | 1 | |a Larratt, Loree |e investigator |4 oth | |
| 700 | 1 | |a Lee, Gyeong-Won |e investigator |4 oth | |
| 700 | 1 | |a Lee, Jae Hoon |e investigator |4 oth | |
| 700 | 1 | |a Lee, Je-Hwan |e investigator |4 oth | |
| 700 | 1 | |a Lee, Jong Wook |e investigator |4 oth | |
| 700 | 1 | |a Lin, Chien-Chin |e investigator |4 oth | |
| 700 | 1 | |a Lukina, Elena |e investigator |4 oth | |
| 700 | 1 | |a Martynova, Elena |e investigator |4 oth | |
| 700 | 1 | |a Matsumura, Itaru |e investigator |4 oth | |
| 700 | 1 | |a Meike, Galina |e investigator |4 oth | |
| 700 | 1 | |a Menosi Gualandro, Sandra Fátima |e investigator |4 oth | |
| 700 | 1 | |a Minaeva, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Mori, Yasuo |e investigator |4 oth | |
| 700 | 1 | |a Morita, Kimio |e investigator |4 oth | |
| 700 | 1 | |a Morselli Ramalho, Fernanda Maria |e investigator |4 oth | |
| 700 | 1 | |a Mun, Yeung-Chul |e investigator |4 oth | |
| 700 | 1 | |a Muus, Petra |e investigator |4 oth | |
| 700 | 1 | |a Myasnikov, Alexander |e investigator |4 oth | |
| 700 | 1 | |a Naito, Kensuke |e investigator |4 oth | |
| 700 | 1 | |a Ninomiya, Haruhiko |e investigator |4 oth | |
| 700 | 1 | |a Nogami, Ayako |e investigator |4 oth | |
| 700 | 1 | |a Notaro, Rosario |e investigator |4 oth | |
| 700 | 1 | |a Ojeda Gutierrez, Emilio |e investigator |4 oth | |
| 700 | 1 | |a Okada, Masaya |e investigator |4 oth | |
| 700 | 1 | |a Okamoto, Shinichiro |e investigator |4 oth | |
| 700 | 1 | |a Olkhovik, Tatiana |e investigator |4 oth | |
| 700 | 1 | |a Pane, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Paquette, Ronald |e investigator |4 oth | |
| 700 | 1 | |a Park, Joon Seong |e investigator |4 oth | |
| 700 | 1 | |a Peffault de la Tour, Régis |e investigator |4 oth | |
| 700 | 1 | |a Piatek, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Piekarska, Agnieszka |e investigator |4 oth | |
| 700 | 1 | |a Pontes Reis, Marcos Laercio |e investigator |4 oth | |
| 700 | 1 | |a Pospelova, Tatiana |e investigator |4 oth | |
| 700 | 1 | |a Ptushkin, Vadim |e investigator |4 oth | |
| 700 | 1 | |a Roeth, Alexander |e investigator |4 oth | |
| 700 | 1 | |a Rojnuckarin, Ponlapat |e investigator |4 oth | |
| 700 | 1 | |a Rosa Pessoa, Viviani de Lourdes |e investigator |4 oth | |
| 700 | 1 | |a Rossi, Blanca |e investigator |4 oth | |
| 700 | 1 | |a Salleh, Sinari |e investigator |4 oth | |
| 700 | 1 | |a Salvino de Araujo, Marco Aurelio |e investigator |4 oth | |
| 700 | 1 | |a Samuel, Desmond |e investigator |4 oth | |
| 700 | 1 | |a Saraeva, Natalya |e investigator |4 oth | |
| 700 | 1 | |a Schrezenmeier, Hubert |e investigator |4 oth | |
| 700 | 1 | |a Shatokhin, Yury |e investigator |4 oth | |
| 700 | 1 | |a Shelekhova, Tatiana |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 109(2022), 3 vom: 01. Sept., Seite 205-214 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2022 |g number:3 |g day:01 |g month:09 |g pages:205-214 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.13783 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2022 |e 3 |b 01 |c 09 |h 205-214 | ||